Cargando…

Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis

RATIONALE: Stress is a risk factor for psychosis and treatments which mitigate its harmful effects are needed. Cannabidiol (CBD) has antipsychotic and anxiolytic effects. OBJECTIVES: We investigated whether CBD would normalise the neuroendocrine and anxiety responses to stress in clinical high risk...

Descripción completa

Detalles Bibliográficos
Autores principales:	Appiah-Kusi, E., Petros, N., Wilson, R., Colizzi, M., Bossong, M. G., Valmaggia, L., Mondelli, V., McGuire, P., Bhattacharyya, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113209/ https://www.ncbi.nlm.nih.gov/pubmed/31915861 http://dx.doi.org/10.1007/s00213-019-05442-6

Ejemplares similares

Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis
por: Wilson, Robin, et al.
Publicado: (2019)

17.3 EFFECT OF CANNABIDIOL ON SYMPTOMS, DISTRESS AND NEUROPHYSIOLOGICAL ABNORMALITIES IN CLINICAL HIGH-RISK FOR PSYCHOSIS PATIENTS: A PLACEBO-CONTROLLED STUDY
por: Bhattacharyya, Sagnik, et al.
Publicado: (2018)

T145. EFFECTS OF CANNABIDIOL ON EMOTION PROCESSING IN PSYCHOSIS RISK: AN FMRI INVESTIGATION
por: Davies, Cathy, et al.
Publicado: (2020)

A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis
por: Davies, Cathy, et al.
Publicado: (2020)

Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: a preliminary report
por: Davies, Cathy, et al.
Publicado: (2021)

Human Striatal Response to Reward Anticipation Linked to Hippocampal Glutamate Levels
por: Bossong, Matthijs G, et al.
Publicado: (2018)

Acceptability of cannabidiol in patients with psychosis
por: Chesney, Edward, et al.
Publicado: (2022)

Cannabidiol (CBD) as a novel treatment in the early phases of psychosis
por: Chesney, Edward, et al.
Publicado: (2021)

S152. CANNABIDIOL INDUCED MODULATION OF MEDIOTEMPORAL ACTIVITY DURING A VERBAL MEMORY TASK IN FIRST-EPISODE PSYCHOSIS
por: O’Neill, Aisling, et al.
Publicado: (2018)

Cannabidiol as a potential treatment for psychosis
por: Davies, Cathy, et al.
Publicado: (2019)

Cannabidiol modulation of hippocampal glutamate in early psychosis
por: O’Neill, Aisling, et al.
Publicado: (2021)

The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review
por: Batalla, Albert, et al.
Publicado: (2019)

Basic Self-Disturbances Related to Reduced Anterior Cingulate Volume in Subjects at Ultra-High Risk for Psychosis
por: Bonoldi, Ilaria, et al.
Publicado: (2019)

Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis
por: Colizzi, Marco, et al.
Publicado: (2019)

HPA-axis function and grey matter volume reductions: imaging the diathesis-stress model in individuals at ultra-high risk of psychosis
por: Valli, I, et al.
Publicado: (2016)

17. CANNABIDIOL AS A TREATMENT IN DIFFERENT STAGES OF PSYCHOSIS- EFFICACY AND MECHANISMS
por: Bhattacharyya, Sagnik
Publicado: (2018)

Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition
por: Colizzi, Marco, et al.
Publicado: (2017)

Cortical GABA in Subjects at Ultra-High Risk of Psychosis: Relationship to Negative Prodromal Symptoms
por: Modinos, Gemma, et al.
Publicado: (2017)

M163. GLUTAMATE METABOLITES ARE ASSOCIATED WITH ALTERED HIPPOCAMPAL ACTIVATION BUT NOT HIPPOCAMPAL-STRIATAL CONNECTIVITY IN SUBJECTS WITH A CLINICAL HIGH RISK FOR PSYCHOSIS
por: Hird, Emily, et al.
Publicado: (2020)

Comorbid Depressive and Anxiety Disorders in 509 Individuals With an At-Risk Mental State: Impact on Psychopathology and Transition to Psychosis
por: Fusar-Poli, Paolo, et al.
Publicado: (2014)

Improving Prognostic Accuracy in Subjects at Clinical High Risk for Psychosis: Systematic Review of Predictive Models and Meta-analytical Sequential Testing Simulation
por: Schmidt, André, et al.
Publicado: (2017)

Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses
por: Umpierrez, Laísa S., et al.
Publicado: (2022)

Cortisol Responses to Naturally Occurring Psychosocial Stressors Across the Psychosis Spectrum: A Systematic Review and Meta-Analysis
por: Cullen, Alexis E., et al.
Publicado: (2020)

Formal thought disorder in people at ultra-high risk of psychosis
por: Demjaha, Arsime, et al.
Publicado: (2017)

The Impact of Cannabidiol on Human Brain Function: A Systematic Review
por: Batalla, Albert, et al.
Publicado: (2021)

Alterations in White Matter Evident Before the Onset of Psychosis
por: Carletti, Francesco, et al.
Publicado: (2012)

Association of Adverse Outcomes With Emotion Processing and Its Neural Substrate in Individuals at Clinical High Risk for Psychosis
por: Modinos, Gemma, et al.
Publicado: (2019)

Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition
por: Colizzi, Marco, et al.
Publicado: (2020)

The Neural Substrate of Reward Anticipation in Health: A Meta-Analysis of fMRI Findings in the Monetary Incentive Delay Task
por: Wilson, Robin Paul, et al.
Publicado: (2018)

Services for people at high risk improve outcomes in patients with first episode psychosis
por: Fusar‐Poli, P., et al.
Publicado: (2015)

F220. THREAT ANTICIPATION AND NEGATIVE AFFECT IN EARLY PSYCHOSIS
por: Chavez-Baldini, UnYoung, et al.
Publicado: (2018)

Prevalence of Neuroradiological Abnormalities in First-Episode Psychosis: A Systematic Review and Meta-analysis
por: Blackman, Graham, et al.
Publicado: (2023)

The Provision of Education and Employment Support At the Outreach and Support in South London (OASIS) Service for People at Clinical High Risk for Psychosis
por: Tognin, Stefania, et al.
Publicado: (2019)

17.2 EFFICACY OF CANNABIDIOL IN THE TREATMENT OF EARLY PSYCHOSIS.
por: Ranganathan, Mohini, et al.
Publicado: (2018)

Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for altered volume striatal glutamate relationships in patients with a history of cannabis use in early psychosis
por: Sami, Musa, et al.
Publicado: (2020)

Self-reported Cannabidiol (CBD) Use for Conditions With Proven Therapies
por: Leas, Eric C., et al.
Publicado: (2020)

Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products
por: Chesney, Edward, et al.
Publicado: (2020)

The Autism–Psychosis Continuum Conundrum: Exploring the Role of the Endocannabinoid System
por: Colizzi, Marco, et al.
Publicado: (2022)

Structural Network Disorganization in Subjects at Clinical High Risk for Psychosis
por: Schmidt, André, et al.
Publicado: (2017)

Descriptive Psychopathology of the Acute Effects of Intravenous Delta-9-Tetrahydrocannabinol Administration in Humans
por: Colizzi, Marco, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6a0mmt56vt7bpre359op0vouvo